Skip to content
Back to search

NCT07895693Recruiting

Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability Study

Summary

People who receive an allogeneic stem cell transplant often face important physical and emotional challenges during their recovery. Even after leaving the hospital, they may experience symptoms such as fatigue, pain, anxiety, uncertainty, or difficulties returning to their usual daily activities. Family caregivers may also experience a considerable burden during this period. Palliative care is specialized supportive care aimed at improving quality of life for people facing serious illness. It focuses on helping patients and families manage symptoms, cope with emotional and practical challenges, and receive care that is aligned with their needs and priorities. While palliative care is increasingly integrated into cancer care, it is not routinely offered to all patients recovering from stem cell transplantation. The COMPAS study aims to determine whether it is feasible and acceptable to systematically offer palliative care consultations to patients after allogeneic stem cell transplantation. Participants will receive supportive consultations with a palliative care physician in addition to their usual transplant follow-up care. The study will evaluate whether patients are willing to participate, whether the consultations can be delivered as planned, and how patients and caregivers perceive this approach. Participants and caregivers will also be invited to complete questionnaires and some may take part in interviews about their experience. The results of this study will help determine whether a larger future study should be conducted and may contribute to improving supportive care for people recovering from stem cell transplantation.

Inclusion criteria

• Adults aged 18 years or older. • Undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). • Meet at least one of the following vulnerability criteria: Heavy symptom burden, defined as a score of 3 or higher for at least one symptom on the Edmonton Symptom Assessment System (ESAS); Age 65 years or older; Poor prognosis, defined as a Disease Risk Index (DRI) category of intermediate, high, or very high. • Able to provide written informed consent. • Able to communicate in French and complete study assessments.

Exclusion criteria

• Severe cognitive impairment preventing completion of study questionnaires. • Inability to provide informed consent. • Inability to communicate in French.

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Recruiting
Phase
No phase (N/A)
Study type
Interventional
Countries
Switzerland
Sponsor
Lisa Hentsch(Other)
Protocol no.
COMPAS
Conditions
Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Behavioral

Treatments studied

  • Early Integrated Palliative Care

Locations · 1

  • Geneva, SwitzerlandGeneva University HospitalsRecruiting at this site

In total, worldwide, the only site listed in the registry is recruiting.

Site status per the ClinicalTrials.gov registry (last update posted: October 26, 2026).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.